Apretude Shortage: What Providers and Prescribers Need to Know in 2026

As of early 2026, Apretude (cabotegravir extended-release injectable suspension) is not listed on the FDA Drug Shortage Database, and ViiV Healthcare has not issued any supply disruption notices. However, providers across the country continue to encounter real access barriers when trying to offer injectable PrEP to their patients. This clinical update synthesizes what prescribers need to know.

Supply Status: FDA Shortage Database Confirms No Official Shortage

Apretude is manufactured by ViiV Healthcare and distributed through specialty pharmacy channels. The drug does not flow through traditional retail or wholesale pharmacy networks. As of early 2026:

No FDA shortage status

No manufacturer-reported supply constraints

No import alerts or recalls

Single-source manufacturer (no generic); ViiV Healthcare Durham, NC

Why Patients and Providers Still Experience Access Barriers

The access gap for Apretude is primarily a delivery infrastructure problem, not a supply problem. Providers considering adding Apretude to their practice face a distinct set of operational requirements:

Specialty pharmacy partnerships: Apretude cannot be ordered through standard wholesale distributors. Practices must establish a working relationship with a specialty pharmacy that stocks and ships Apretude (often TheraCom, through ViiVConnect).

Medical vs. pharmacy benefit billing: Because it's clinic-administered, Apretude is often billed under the medical benefit (buy-and-bill model) or pharmacy benefit (via specialty pharmacy to practice). Practices must determine which pathway their payer mix requires.

Mandatory HIV testing before each injection: The boxed warning requires HIV-1 testing with an FDA-approved diagnostic test before each injection. This requires a testing protocol and, ideally, a point-of-care HIV test available in the practice.

Prior authorization management: Some payers require prior authorization despite ACA mandates. Practices need PA workflows in place.

Clinical Reminders: Boxed Warning and Pre-Administration Protocol

Apretude carries a Boxed Warning regarding risk of drug-resistant HIV-1 in individuals with undiagnosed HIV-1 infection. The clinical protocol before each injection must include:

Confirm HIV-1 negative status using an FDA-approved test for acute/primary HIV (HIV-1 RNA test to confirm if antigen/antibody test is used)

Review current medications for contraindicated UGT1A1/1A9 inducers (carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifapentine, apalutamide)

Assess for hepatic symptoms; monitor liver function as clinically indicated

Screen for depressive symptoms and suicidal ideation

Administer as 600 mg (3 mL) gluteal IM injection only — NOT IV or subcutaneous

Managing Missed or Late Injections

Apretude's extended-release pharmacokinetics create unique challenges with missed doses. The drug has a prolonged pharmacokinetic tail — residual concentrations can remain in systemic circulation for up to 12 months after the last injection, but at sub-therapeutic protective levels.

If a patient's scheduled injection is missed or delayed by more than 7 days, current FDA guidance recommends oral cabotegravir (Vocabria) 30 mg daily as a bridge, starting approximately 2 months after the last Apretude injection, for up to 2 months, with resumption of injections on the last day of oral dosing or within 3 days.

Insurance and Reimbursement: What Practices Need to Know

The ACA mandates $0 cost-sharing for Apretude and related PrEP services (HIV testing, counseling, office visit) for most commercial plans and Medicaid expansion programs. Medicare covers it at $0 under preventive services. However, implementation is uneven:

Some payers still require prior authorization — your office should have a PA team or template letters

Billing may need to be split: medication (J-code or specialty pharmacy), injection administration (CPT 96372 or 96401 depending on context), and the preventive visit (99381-99397)

ViiVConnect offers reimbursement support services — consider enrolling your practice

Patient Assistance Programs Available

For patients who cannot access Apretude through insurance:

ViiV Apretude Savings Program: Commercially insured patients may pay as little as $0. Enroll at ViiVConnect.com.

ViiV Patient Assistance Program: Uninsured patients with limited income can receive Apretude at no charge. Call 1-844-588-3288.

State AIDS Drug Assistance Programs (ADAPs): Many state ADAPs cover PrEP including injectable options. Check your state's ADAP formulary.

How medfinder Supports Your Practice

When your patients are struggling to find Apretude or bridge medications, direct them to medfinder. medfinder for Providers also offers resources to help your practice navigate medication access challenges.